OP Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

OP Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.94M	Sell	11,482 -7,024	-38%	-$1.04M	0.02%	480
2026 Q1	$2.44M	Buy	18,506 +6,988	+61%	+$927K	0.02%	400
2025 Q4	$1.63M	Hold	11,518	–	–	0.02%	496
2025 Q3	$1.62M	Hold	11,518	–	–	0.02%	504
2025 Q2	$1.45M	Buy	11,518 +889	+8%	+$102K	0.02%	532
2025 Q1	$1.18M	Buy	+10,629	New	+$1.35M	0.02%	570

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PBBUPS

PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return

Aware Super Sydney, Australia $7.06B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

OP Asset Management's NBIX Position: Q2 2026 in Review

OP Asset Management reduced its Neurocrine Biosciences (NBIX) stake by 38% in Q2 2026, selling an estimated $1.04M and leaving 11,482 shares worth $1.94M. The position accounts for 0.02% of the portfolio, ranked #480.

OP Asset Management first reported a position in NBIX in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.44M in Q1 2026. 260 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

OP Asset Management held 11,482 shares of Neurocrine Biosciences worth $1.94M as of Q2 2026.
OP Asset Management sold 7,024 Neurocrine Biosciences shares in Q2 2026, an estimated $1.04M.
Neurocrine Biosciences made up 0.02% of OP Asset Management's portfolio in Q2 2026, its #480 holding.
OP Asset Management first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 6 quarters since.
OP Asset Management's Neurocrine Biosciences position peaked at $2.44M in Q1 2026.
260 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on OP Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.